Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134047 | 0.89 | PTPN1 (0.48) | PTPN1PTPN2RETALDH1A1DYRK1A | |
| SCHEMBL5367282 | 0.86 | KMT2A (0.60) | PTPN1PTPN2RETALDH1A1DYRK1A | |
| SCHEMBL5369248 | 0.84 | RET (0.65) | PTPN1PTPN2RETALDH1A1DYRK1A | |
| SCHEMBL5366390 | 0.81 | ALDH1A1 (0.45) | PTPN1RETALDH1A1DYRK1AMEN1 | |
| SCHEMBL5357851 | 0.81 | RET (0.53) | PTPN1PTPN2RETALDH1A1MEN1 | |
| SCHEMBL7133824 | 0.80 | PSEN1 (0.52) | RETMAPT | |
| SCHEMBL5728121 | 0.78 | POLB (0.69) | PTPN1PTPN2ALDH1A1DYRK1AMEN1 | |
| SCHEMBL6304861 | 0.78 | POLB (0.69) | PTPN1PTPN2ALDH1A1DYRK1AMEN1 | |
| SCHEMBL5728117 | 0.78 | POLB (0.69) | PTPN1PTPN2ALDH1A1DYRK1AMEN1 | |
| SCHEMBL5373780 | 0.78 | EGFR (0.64) | RETALDH1A1ALOX12MAPTRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PTPN1 882/4885PTPN2 1051/4885RET 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.